MET amplification is found in 2–4% of primary NSCLC tumors [5, 6], and is a common mechanism of acquired resistance to epidermal growth factor receptor (EGFR) TKIs [7, 8] as well as other oncogenic drivers [9–11]. This evidence concerns the gene MET and non-small cell lung carcinoma.